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Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease,
worldwide. With the development of direct-acting antivirals, treatment of chronically infected
patients has become highly effective, although a subset of patients responds less well to
therapy. Sofosbuvir is a common component of current de novo or salvage combination
therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome
sequences of HCV from 507 patients infected with HCV subtype 3a and treated with
sofosbuvir containing regimens to detect viral polymorphisms associated with response to
treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 pro-
teins are associated with reduced treatment response. These polymorphisms are enriched in
post-treatment HCV sequences of patients unresponsive to treatment. They are also asso-
ciated with lower reductions in viral load in the first week of therapy. Using in vitro short-term
dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir
potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The
identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment
outcomes emphasises the value of systematic genome-wide analyses of viruses in unco-
vering clinically relevant polymorphisms that impact treatment.
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An estimated 70 million people worldwide are persistentlyinfected with hepatitis C virus (HCV), a major aetiologyof chronic liver disease, which can culminate in cirrhosis
and hepatocellular carcinoma1. Since 2011, the rapid develop-
ment of oral direct-acting antivirals (DAA) that target three
different HCV non-structural (NS) proteins has resulted in sig-
nificant improvements in the safety and efficacy of treatments
that cure HCV infection (sustained virologic response (SVR)).
Combinations of DAAs targeting different HCV proteins reg-
ularly achieve SVR rates in excess of 95%2,3.
Sofosbuvir is a nucleotide analogue and competitively binds to
and blocks the HCV NS5B polymerase and inhibits viral
replication4,5. Sofosbuvir is a key component in several currently
utilised treatment regimens and is recommended for use in
combination with other DAAs, such as NS5A inhibitors ledi-
pasvir, daclatasvir or velpatasvir and the NS3 protease inhibitor
voxilaprevir. Sofosbuvir in combination with velpatasvir and
voxilaprevir has become one of the recommended salvage regi-
mens for patients unresponsive to previous DAA therapies6,7.
Sofosbuvir is effective against all HCV genotypes and has a high
barrier to the development of resistance8. However, pre-treatment
resistance-associated substitutions (RAS) for both NS3 protease
and NS5A inhibitors used in combination with sofosbuvir9–12 are
commonly reported. Subtypes 3b and 4r have been shown to be
inherently resistant to available NS5A inhibitors13. Where RAS
are present, they can cause a large reduction in the potency of
NS3 protease and NS5A inhibitors, making sofosbuvir the main
active compound in these regimens.
Only a small number of sofosbuvir-associated RAS have been
reported8,14 relative to other DAAs. In multiple clinical trials
using sofosbuvir, NS5B substitutions L159F, S282T, C316H/N,
L320F and V321A are reported as RAS and have been detected
post-treatment in patients who do not achieve SVR14, although
only in a small subset. The acquisition of these RAS has been
shown to have a large fitness cost for the virus in vitro11 and thus
they rarely persist for long after treatment failure15. An exception
is the S282T RAS, which can persist if compensatory mutations
are also acquired16. Certain HCV subtypes (4r) have been shown
to acquire this substitution more readily9,10. Furthermore, with
the exception of S282T, all sofosbuvir RAS show negligible
increases in resistance using in vitro models11 and patients who
were unresponsive to sofosbuvir containing regimens, often do
not carry any of these RAS at baseline or post-treatment. We
recently reported the NS5B A150V polymorphism as conferring
resistance to sofosbuvir17 using patient data and in vitro assays,
although others have shown no effect on sofosbuvir resistance in
other in vitro assays18. This polymorphism unlike previously
reported substitutions is common in pre-treatment HCV subtype
3a sequences and may reduce access to the active site of the HCV
polymerase19. To date, the mechanism of treatment failure in the
small proportion of individuals who do not respond to
sofosbuvir-based regimens remains unknown. Most studies of
sofosbuvir RAS have focused on NS5B protein and the compar-
ison of the post-treatment to baseline sequences, which can only
detect treatment emergent RAS. Investigating the impact of the
pre-existing polymorphisms in NS5B and other HCV proteins
could provide novel insight into viral determinants of sofosbuvir
treatment and help us stratify patients more effectively.
In this work, we use full length HCV genomes and deep-
sequencing data from 507 patients with HCV gt3a infection and
treated with sofosbuvir as the only DAA (sofosbuvir+
ribavirin ± Interferon alpha, see “Methods” for cohort and treat-
ment details) from the BOSON clinical trial20, to identify viral
determinants of sofosbuvir treatment outcome. We perform a
viral genome-wide association study (V-GWAS) of baseline
sequences and identify three viral polymorphisms outside the
NS5B protein, that are significantly associated with SVR and we
refer to as treatment outcome polymorphisms (TOPs). Addi-
tionally, we find a stepwise reduction in the SVR rate associated
with an increase in the total number of TOPs. The TOPs are also
associated with a lower reduction in viral load during the first
week of therapy and are enriched in the post-treatment sequences
in patients who did not achieve SVR. We perform in vitro short-
term sofosbuvir dose-response assays using DBN3acc mutants for
each TOP and their combinations but observe a negligible impact
on the efficacy of sofosbuvir indicating a mechanism of action
possibly independent of drug binding. The approach demon-
strates the potential of genome-wide assessment of viral
sequences to provide unexpected insight into molecular interac-
tions and their importance in improving treatment of viral
infections.
Results
Non-viral factors associated with SVR. Baseline whole genome
HCV sequences were generated for 568 patients enrolled in the
BOSON study20,21, 518 of which were gt3, 49 were gt2 and one
was a gt1a/2b recombinant virus. HCV is a highly diverse
pathogen and to limit the impact of virus population structure on
our analysis, we restricted the analyses to samples from patients
infected with subtype 3a (N= 507). Overall 82% (416/507) of the
gt3a patients achieved SVR.
To account for non-viral factors associated with SVR, we used
logistic regression to test for association between treatment
outcome and patient’s cirrhosis status, gender, baseline viral load,
prior IFN-based treatment and IFNL4 SNP rs12979860 genotypes
(CC vs non-CC) in a multivariate model. Cirrhosis status was
significantly associated with SVR (P= 1.5 × 10−4), having the
largest impact on treatment response (failure rate in cirrhotic
patients 29%= 47/163 and in non-cirrhotic patients 13%= 44/
344). Male gender and the non-CC genotype of the IFNL4 SNP
rs12979860 were also significantly associated with increase in
treatment failure rate (Pgender= 0.016, PIFNL4= 6.4 × 10−3).
Previous IFN-based treatment and higher viral load were
associated with statistically non-significant increases in treatment
failure (Supplementary Fig. 1). In all our subsequent regression-
based analysis INFL4 genotype, cirrhosis, gender, previous IFN-
based treatment and log10 of baseline viral load were added as
covariates to account for possible confounders.
During the BOSON clinical trial, patients were randomised
into three treatment arms of sofosbuvir and ribavirin for 16 weeks
(16 SOF+ RBV), sofosbuvir and ribavirin for 24 weeks (24
SOF+ RBV), or sofosbuvir plus ribavirin and peginterferon-alfa
for 12 weeks (12 SOF+ RBV+ IFN). These treatment arms had
different SVR rates, but as patients were randomised into these
treatment arms (which means viruses were also randomised), the
confounding between viral factors and the treatment arms is
minimised. We therefore decided not to include treatment arm as
a covariate in our analysis as it reduces the power of the tests, but
have investigated the association between TOPs and the
treatment arms to ensure there is no correlation between the two.
Previously reported sofosbuvir RAS. We investigated the base-
line sequences for presence of previously reported sofosbuvir RAS
in the NS5B protein (A150V, L159F, S282T, C316H/N, L320F
and V321A)8,14,22. Only A150V (n= 204) and L159F (n= 1)
were detected in the consensus sequences (sequence data for these
sites was not available for six patients). A150V was significantly
associated with outcome (P= 4.92 × 10−3) and patients carrying
valine at this site had an SVR rate of 75% (n= 153/204) vs. 86%
(n= 257/297) for patients with other amino acids at this site. We
have previously reported this association in a subset of this cohort
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and showed it reduces sensitivity to sofosbuvir using in vitro
assays17. We have also previously reported an association between
this viral site and host IFNL4 SNP rs1297986021 genotypes. Strati-
fying the patients based on the IFNL4 SNP rs12979860 genotypes
(CC vs. non-CC (genotyping data not available for two patients)), we
observed that, among CC patients, the impact of valine on SVR rate
was minimal (SVRvaline 85%= 35/41, SVRnon-valine 87%= 129/148,
Fisher’s exact test P= 0.80). On the contrary, among non-CC
patients it reduced SVR rate substantially (SVRvaline 72%= 117/162,
SVRnon-valine 85%= 127/148, Fisher’s exact test P= 0.0036). How-
ever, the interaction term was statistically nonsignificant (P= 0.36).
Analysis of minor populations in the NGS data revealed
very low frequencies (<1% of reads) of S282T (two patients),
C316N (one patient), L320F (two patients) and V321A (eight
patients).
Identification of TOPs using viral genome-wide association
study (V-GWAS). A major advantage of HCV whole-genome
sequencing is the possibility of testing viral genetic variants for
associations with SVR across the entire viral genome to identify
potentially novel associations between HCV genetic variants and
response to sofosbuvir treatment. Initially, we investigated whe-
ther any of the HCV lineages were associated with treatment
outcome. To do this we built a maximum likelihood phylogenetic
tree (Supplementary Fig. 2) from baseline consensus sequences.
Analysis by treeBreaker software23 did not reveal any clades that
had a different SVR rate from the rest of the tree (Bayes fac-
tor= 0.969, see “Methods”).
We then performed a V-GWAS, using logistic regression to
test for association between sofosbuvir treatment outcome and
encoded amino acids at each site, including the non-viral factors
previously indicated as covariates. The first three viral genetic
principal components (PCs) and the first three host genetic PCs
were also included as covariates to account for host-virus
population co-structuring. In our analysis, SVR status was used
as the response variable and the presence and absence of each
amino acid as the explanatory variable. We only tested amino
acids that were present in sequences from at least 20 individuals;
this resulted in 1010 tests at 484 sites. At a false-discovery rate
(FDR) of 15%, three viral polymorphisms were significantly
associated with SVR (Fig. 1 and Supplementary Table 1, the
numbers below may not add to 507 as not all sites on the viral
polyprotein were available for all samples, see Supplementary
Table 1). The most significant association with SVR was at
position 132 in the NS2 protein (P= 1.05 × 10−5), where
isoleucine (80%= 405/506) and valine (20%= 100/506) alter-
nated (one isolate carried leucine). Valine was associated with a
reduction in treatment response (SVR 66%= 66/100) relative to
the isoleucine residue (86%= 348/405). Two additional signifi-
cant associations with reduction in SVR rate were valine at
position 67 in the NS3 protein (P= 4.71 × 10−4) and alanine at
position 119 in the NS2 protein (P= 5.18 × 10−4) (Fig. 1,
Supplementary Table 1 and Supplementary Table 2). In the
NS5B protein (the direct antiviral target of sofosbuvir), valine at
position 150 was ranked first (lowest P-value, P= 4.92 × 10−3)
although the association was not significant genome-wide at a
15% FDR. For the remainder of this work NS5B A150V is
included as a TOP.
Next we used an alternative chronic HCV infection cohort of
144 patients provided by HCV Research UK to replicate the
findings. All patients had cirrhosis and 107 (75%) were treated
with sofosbuvir in combination with an additional NS5A
inhibitor such as daclatasvir, ledipasvir or velpatasvir, while the
remaining 37 (25%) patients were treated either with SOF+ RBV
or SOF+ RBV+ INF. In this replication cohort, only NS2 119A
was nominally associated with SVR (P= 0.045). Overall, the
effect size estimates were similar for three of the four TOPs (NS2
119A, NS2 132V and NS5B 150V), but they had larger confidence
intervals due to smaller samples sizes and additional DAAs used
in the therapy (Supplementary Fig. 3).
Covariation of TOPs and their impact on sustained virologic
response. To understand the impact of presence of multiple
TOPs in each sequence on SVR, we stratified patients based on
the number of TOPs present in their baseline consensus
sequences (Fig. 2A). The SVR rate for patients whose virus car-
ried no TOPs was 95% (133/140), which was reduced to 50% (13/
26) for patients with three TOPs. Only one patient carried all four
TOPs and this patient achieved SVR. The step wise reduction in
the SVR rate associated with the increase in the number of TOPs
present at baseline was highly significant (logistic regression
P= 6.6 × 10−10).
We also investigated the covariation between these TOPs and
their impact on SVR. NS2 119A was excluded from this analysis
because of its low frequency (4%= 22/505). We tested for
association (covariation) between the three pairs using logistic
regression, including the first three viral PCs and host IFNL4 SNP
rs12979860 genotypes (CC vs. non-CC) as covariates to account
for virus population structure and the impact of IFNL4 on the
HCV amino acids. NS5B 150V was significantly associated with
NS2 132V (P= 0.004) and nominally with NS3 67V (P= 0.02).
NS2 132V and NS3 67V were not significantly associated with
each other (P= 0.83). Stratifying the patients by presence and
absence of TOPs (valine residue) at the three sites of NS2 132,
NS3 67 and NS5B 150, we observed that patients carrying viruses
with non-valine residues at all three sites had the highest SVR rate
(94%= 140/149), while carrying any one of these TOPs
individually or in combination reduced SVR rate significantly
(Fig. 2B). Carrying valine at both NS2 132 and NS3 67 sites, but
not NS5B 150 was associated with the lowest SVR rate of 50%
(P= 2.4 × 10−6). We also tested for non-additive interaction
effects on SVR between the three sites and found that the only
significant non-additive interaction effect was between NS2 132
and NS5B 150 sites (interaction P= 0.01) where carrying valine
at both sites resulted in SVR recovery (79%= 22/28) rather than
an additive reduction.
TOPs effects on viral load reduction during first week of
therapy. If these TOPs reduce the impact of treatment, one
expects to observe differences in the reduction in viral load during
therapy between patients with and without these TOPs. Thus, we
evaluated the impact of these novel TOPs on the viral load
reduction from baseline to week one of therapy and tested for
difference in mean reduction between patients with and without
each TOP and also their combination (Fig. 3). At each of the sites,
the mean reduction in viral load was smaller for TOPs relative to
non-TOPs residues. The reduction in viral load was nominally
significant for patients whose virus carried TOPs at sites NS2 119
(P= 0.013), NS2 132 (P= 0.018) or NS3 67 (P= 0.029) relative
to those whose virus did not carry the TOPs at these sites. The
impact of the total number of TOPs carried by each patient on
the viral load reduction was also significant (linear regression,
P= 0.006, Fig. 3B). Investigating the eight possible combinations
of the three sites of NS2 132, NS3 67 and NS5B 150 we observed
that the presence of valine at the two sites of NS2 132 and NS3 67
and non-valine at NS5B 150 resulted in the lowest reduction in
viral load during therapy (P= 0.00091, Supplementary Fig. 4).
We also tested for association between the TOPs and the baseline
viral load (log10 viral load). The NS2 119 A TOP was nominally
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associated with a higher viral load (P= 0.029, linear regression),
none of the other TOPs were associated with baseline viral load.
Prevalence and enrichment of TOPs in post treatment
sequences. Ninety-one patients in this trial did not achieve SVR
and we were able to generate 73 whole-genome consensus
sequences from plasma samples taken at 12 weeks post-treatment
(12WPT). These consensus sequences were scanned for the pre-
sence of previously reported sofosbuvir RASs. NS5B 159F was
detected in four isolates. This represents a significant change in
the distribution of this RAS in the post treatment sequences
relative to the baseline sequences (binomial test, P= 1.65 × 10−5).
The NS5B RAS 282T, 316H/N, 320F and 321A were not detected
in any of the post treatment consensus sequences. On analysis of
the quasi-species data the 159F was detected in two additional
12WPT samples as minor variant (<15% of reads). The 321A was
detected at low frequencies (<1% of reads) in two samples.
We also investigated the distribution of the TOPs identified
using baseline sequences in our study in the 12WPT sequences. A
binomial test was performed to identify changes in the
distribution of the TOPs at these sites between the baseline
population and the 12WPT sequences (Table 1). NS5B 150V was
significantly enriched in the 12WPT sequences (P= 0.00088) and
NS2 132V (P= 0.019) and NS3 67V (P= 0.023) were nominally
significantly enriched. The majority of these polymorphisms were
present at baseline and were carried forward to the post-
treatment isolates, suggesting that the increase in prevalence is
due to enrichment of pre-existing polymorphisms rather than
substitutions during therapy. However, this was not the case for
the previously reported NS5B 159F RAS, where three of the four
RAS had developed during therapy.
In vitro evaluation of sofosbuvir antiviral activity against TOPs
using a cell culture adapted genotype 3a isolate (DBN3acc
system). We investigated the effect of the TOPs using short-term
dose-response sofosbuvir assays, which reflect drug binding. The
cell culture adapted genotype 3a DBN3acc virus was mutated
using site directed mutagenesis18,24 to contain individual and
combinations of TOPs (see Methods); a full list of the mutants
tested can be found in Table 2. All the TOP containing mutants
were viable after transfection except for the combination of NS2
119A, NS2 132V and NS5B 150V. The NS2 132V mutant
exhibited a slight delay in viral spread after transfection, whereas
the remaining mutants propagated and produced infectious
viruses similar to the original cell culture adapted DBN3acc virus
(Table 2). All viruses were genetically stable after passage,
maintaining the introduced mutations. We did observe the
emergence of a population harbouring two extra mutations
(A4506A/G (amino acid I1389I/M) in NS3 and A7480A/G
(amino acid T2381T/A) in NS5A) in the DND3acc NS2 132V
virus (present at 50% together with the original residue as indi-
cated in Sanger sequencing). None of the differences in the EC50
between mutants and the original virus reached a 2-fold thresh-
old, which we considered as a minimum to be recognised as
providing decreased activity of sofosbuvir in this particular assay
(Table 2, dose response curves can be found in Supplementary
Fig. 5).
Association of TOPs and host HLA alleles. We examined the
association between the TOPs and the host HLA alleles and their
restricted epitopes. The TOPs NS2 119A and NS2 132V are both
found within previously identified HCV gt3a T-cell epitopes25. To
investigate if the host HLA alleles can explain the TOPs asso-
ciation with treatment outcome, first we investigated if any of the
HLA alleles were associated with treatment outcome. We used
logistic regression with the same covariates as in the V-GWAS to
test for association between the HLA alleles and SVR. To retain
power, we only tested at the two-digit level and only tested HLA
alleles present in at least 20 individuals. At 20% FDR no HLA
allele was significantly associated with treatment outcome (Sup-
plementary Table 3). Next, we tested for association between the
TOPs and the HLA alleles using the same logistic regression
model (Supplementary Table 3). At 20% FDR the only association
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Fig. 1 Association between hepatitis C virus (HCV) amino acids and sofosbuvir-based treatment outcome. A Manhattan plot of association tests
between HCV amino acids and treatment outcome. At each viral site only the p-value for the most associated amino acid is plotted. The dashed line
indicates 15% false discovery rate. For the three sites significantly associated with outcome and the most associated site in the non-structural 5B (NS5B)
protein, the amino acid associated with the lowest cure rate at the site and its position within its respective protein is indicated. B Schematic of HCV
polyprotein.
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if the impact of the NS2 132V on SVR is mediated through its
association with HLA B*55, we tested for association between
SVR and NS2 132V using logistic regression conditioning on
HLA B*55 (including it as a covariate in the model). Con-
ditioning on HLA B*55 had negligible impact on the association
between NS2 132V and SVR (original P= 1.05 × 10−5, model
including B*55, P= 1.17 × 10−5).
Discussion
In this study, we report the first systematic and comprehensive
investigation of the viral determinants of treatment outcome in a
large cohort of HCV gt3a infected patients treated with SOF+
RBV ± /−INF. We generated HCV whole genomes using next
generation sequencing technologies for 507 patients at baseline
and 73 patients who failed therapy at 12WPT. Using V-GWAS
we performed a systematic assessment of the impact of HCV
amino acids across all proteins on sofosbuvir treatment outcome.
In this study we report for the first time, amino acid poly-
morphisms in HCV NS2 and NS3 proteins associated with
treatment outcome. We also examined combinations of TOPs,
the total number of TOPs carried, reduction in viral load during
therapy and post-treatment failure sequences for additional evi-
dence of the impact of these novel TOPs. We expect that with
advances in high-throughput virus whole genome sequencing and
the reduction in cost26, analysis of this kind will become a
powerful tool for understanding the viral genetic variants driving
treatment response and whether stratification of patients is
required based on viral genetics to optimise treatment outcomes.
Traditionally, RAS have been identified in vivo by comparing
baseline sequences to post treatment failure sequences in the protein
targeted by the drug27. However, virus is usually undetectable in
plasma for several weeks after the end of the treatment and the RAS
with high fitness cost to the virus are likely to have reverted back to
the wild type shortly after the end of the treatment. RAS are also
identified in vitro by performing viral selection studies. The majority
of RAS have been tested using in vitro assays to determine their
impact on viral replication in cell culture16. This method has worked
well for protease inhibitors and NS5A inhibitors where there is a
strong corelation between in-vivo and in-vitro data. However, for
nucleotide analogues like SOF this method has been less successful.
Any mutations that reduces the binding of the drug such as NS5B
S282T will also have a high fitness cost to the virus28. The loss off
Fig. 2 Covariation of treatment outcome polymorphisms (TOPs) and their impact on sustained virological response (SVR) rate. A SVR rate for patients
with different numbers of TOPs in baseline sequences. The dots indicate the SVR rate in each group and the lines indicate its 95% confidence intervals. The
numbers in each group are shown at the bottom of the figure. B Covariation between the three novel TOPs and their association with treatment outcome.
Combinations tested are listed in the table on the left. The squares show the estimated effect size (log(odds ratio)) for each group and the lines show its
95% confidence interval estimated from logistic regression. The P-value (logistic regression) and the SVR rate for each group are shown on the right.
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fitness may be reduced by existing TOPs that may reduce fitness cost
of the transient mutations, which reduce the effect of the nucleotide
analogue. This process is difficult to identify from sequencing treat-
ment failures due to the transient nature of the mutations, which
provide resistance. It is also difficult to replicate this using only in-
vitro models due to the complex interactions between HCV proteins
essential to the viral life cycle29,30 and the fact the cell culture models
do not represent the physiological and pathological conditions of a
human liver28,29. Instead a combined approach combining viral
sequence analysis such as V-GWAS and in-vitro analysis is required
to identify the viral factors, which cause nucleotide analogue
resistance.
p = 0.013 p = 0.018 p = 0.029 p = 0.159
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Fig. 3 Reduction in viral load during the first week of therapy and its association with treatment outcome polymorphisms (TOPs). A Reduction in log10
viral load between baseline and week one of therapy stratified by presence and absence of the residue associated with the lowest SVR rate at each TOP (A:
Alanine, non-A: any amino acid other than alanine, V: Valine, non-V: any amino acid other than Valine). n= 507 patients. The mean change in viral load is
shown as a black dot for each TOP and the lines indicate its 95% confidence intervals. P-values for difference in mean calculated using one-sided
Mann–Whitney test. B Reduction in log10 viral load between baseline and week one of therapy against increasing numbers of TOPs (presence or absence
of residue associated with the lowest SVR rate at the target sites). n= 507 patients. The mean change in viral load is shown as a black dot and the lines
indicate its 95% confidence interval. P-value for association between number of TOPS and reduction in log10 viral load calculated using linear regression.
Table 1 Prevalence of resistance associated substitutions (RASs) and treatment outcome polymorphism (TOPs) at baseline and
12 weeks post treatment (12WPT).
Protein RAS/TOP Prevalence at baseline (n) Prevalence at 12WPT (n) P-value Proportion of RAS/TOP at 12WPT not present at
baseline (n)
Previously characterised RAS
NS5B 150V 41% (204/501) 60% (43/72) 8.77 × 10−4 9% (4/43)
NS5B 159F 0% (1/501) 6% (4/72) 1.47 × 10−5 75% (3/4)
TOPs
NS2 119A 4% (22/505) 8% (6/72) 9.37 × 10−2 17% (1/6)
NS2 132V 20% (100/506) 30% (22/72) 1.94 × 10−2 0% (0/21)
NS3 67V 44% (222/506) 56% (41/73) 2.33 × 10−2 7% (3/41)
The percentage of the population with each RAS or TOP is shown at baseline and 12WPT. These distributions were compared using a one-sided binomial test and the P-value is shown (nominal P-value,
not adjusted for multiple comparison). The percentage of patients where the amino acid at baseline has changed to the RAS or TOP in post-treatment sequence is also shown.
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With the benefit of full-length HCV genomic data enabling a
comprehensive analysis of all HCV proteins, we have found
strong evidence that common polymorphisms in HCV NS2 and
NS3 proteins modify treatment outcome in patients receiving
SOF+ RBV ± /−INF. The treatment arm including interferon-
alpha had the highest SVR rate and therefore the mechanism of
action of the TOPs is unlikely to be associated with interferon-
alpha. Although several mechanisms of action for ribavirin have
been proposed31, a main antiviral effect for HCV can be achieved
through genome-wide mutagenesis18, however direct effects on
HCV RNA levels are not observed in patients on ribavirin
monotherapy32. The hereby identified TOP sites have not been
reported in previous studies characterising ribavirin resistance33.
Whilst two of the TOPs were found to be in previously reported
HCV T Cell epitopes25, we did not observe a significant asso-
ciation between SVR and any HLA alleles. At 20% FDR, we found
an association between NS2 132V and HLA B*55. However,
when accounting for the HLA B*55, the impact of NS2 132V on
SVR did not change.
A plausible mechanism of action of these TOPs is that they
may reduce the antiviral effect of sofosbuvir by directly affecting
the viral life cycle in the presence of sofosbuvir, for instance
modulating replication and assembly or by directly affecting drug
interactions in the replication complex, and therefore influencing
treatment outcome. However, our in vitro cell culture analysis of
TOPs demonstrated no evidence of increase in the sofosbuvir
EC50 in short-term dose-response assays, which suggests no sig-
nificant changes in drug affinity. This observation agrees with
prior studies showing that even putative sofosbuvir RASs in the
NS5B protein do not change the EC50 of sofosbuvir unless the
S282T substitution is present34. Thus, even if TOPs do not
directly affect sofosbuvir binding, they may enhance the virus
ability to overcome the inhibition of sofosbuvir by increasing
overall viral fitness in the presence of the drug or by promoting
the transient emergence of mutations (such as S282T) that will
decrease drug binding, these may disappear before the patients
viral load is high enough for detection via sequencing, as they
cause a high fitness cost. This effect may be more evident in less
potent treatments such as SOF+ RBV ± INF and can efficiently
be counteracted in pan-genotypic regimens that include several
potent DAA that can more rapidly inhibit viral replication.
Another study has also identified sites outside the NS5B
associated with sofosbuvir-based treatment outcome, including
sites in similar regions of the NS2 and NS3 protein35. However,
this was in gt1a HCV and in a cohort with only 20 patients.
Sofosbuvir targets the NS5B viral RNA polymerase. Although
NS2 and NS3 proteins are not directly targeted by sofosbuvir,
HCV replication and production are critically dependent on
complex interactions between the viral proteins. HCV NS2 is a
membrane-bound autoprotease that is required for cleavage at the
NS2/NS3 boundary36–39. Autoprotease activity is enhanced by
the N-terminal region of NS336. Although NS2 is dispensable for
HCV RNA replication, the release of NS3 from the polyprotein by
NS2 is essential for viral RNA synthesis to proceed. Aside from its
autoprotease activity, NS2 plays an essential and central role in
assembly of infectious virus, which requires complex interactions
with both structural and non-structural proteins40. The
N-terminal one-third of NS3 also possesses protease activity while
the remaining two-thirds encode a RNA helicase41. The position
of the identified TOPs lies within the protease domains of both
proteins42,43. In NS2, amino acid position 119 lies in a loop
region between two anti-parallel α-helices H1 and H2 while
residue 132 is located in α-helix H242. It has been proposed that
the loop containing residue 119 may lie close to or interact with a
cellular membrane42. Position 67 in the NS3 protease domain sits
in a loop region between two beta sheets43. The functional sig-
nificance of the variants at these positions in NS2 and NS3 on the
virus life cycle is not obvious. Nonetheless, data from in vitro
studies have demonstrated that tissue culture adapted variants in
HCV proteins that include NS2, NS3 and NS5B can modulate
virus production as well as interactions between the viral proteins.
Thus, there is the potential for variants to arise that could modify
the complex protein–protein interactions needed for both HCV
RNA replication and virion assembly, and thereby promote DAA
resistance in proteins that are not obvious targets for the drug44.
By stratifying the patients, we observed that the reduction in
SVR rate based on the combination of these TOPs was broadly
additive with patients having both NS2 132V and NS3 67V
having an SVR rate of 50% vs. 69 and 86% for patients carrying
only NS2 132V or NS3 67V TOP, respectively. Patients with
viruses that did not carry any TOP had an SVR rate of 94%. We
also observed a step-wise reduction in SVR rate as the total
number of TOPs present in baseline sequences increased. In
studying the impact of these TOPs on reduction in viral load
Table 2 Characteristics of HCV DBN3acc mutants after transfection and subsequent passage in Huh7.5 cells.
Mutant Spread (day)a Infectivity titre (day)b Fold Change EC50c Engineered mutations
DBN3acc 10 4.65 (10) N/A Maintained
NS2 119A 10 4.71 (10) 1.02 Maintained
NS2 119V 10 4.76 (10) 1.22 Maintained
NS2 132V 17 4.10 (23) 0.61 Maintainedd
NS3 67A 10 4.49 (10) 0.65 Maintained
NS5B 150V 10 4.50 (14) 1.00 Maintained
NS2 119A+NS2 132V 10 4.62 (14) 1.14 Maintained
NS2 119V+NS2 132V 10 4.33 (14) 0.60 Maintained
NS2 119A+NS3 67A 10 4.51 (10) 1.19 Maintained
NS2 119V+NS3 67A 10 4.40 (10) 1.06 Maintained
NS2 119V+NS2 132V+NS3 67A 10 4.56 (14) 0.98 Maintained
NS2 119A+NS2 132V+NS5B 150Ve N/A N/A N/A N/A
NS2 119V+NS2 132V+NS5B 150V 10 4.39 (14) 0.98 Maintained
NS2 119A+NS3 67A+NS5B 150V 10 4.14 (14) 0.79 Maintained
Viral kinetics, sofosbuvir susceptibility and genetic stability of DBN3acc original and mutant viruses.
aDay of spread after transfection, which corresponds to the day where ≥80% HCV antigen-positive cells were observed in the culture.
bThe highest infectivity titre observed in supernatants harvested after transfection with the day indicated in parenthesis. Data is based on the mean of three replicates and the titre units are Log10 focus-
forming units per millilitre (FFU/ml).
cChange in sofosbuvir susceptibility shown as fold-change in EC50 values between original and mutant viruses.
dThe DBN3acc-NS2I132V mutant virus acquired substitutions A4506A/G (aa I1389I/M in NS3) and A7480A/G (aa T2381T/A in NS5A) as detected during passage.
eRecombinant DBN3acc- NS2 119A+NS2 132V+NS5B 150V was non-viable in two independent transfections. N/A: not applicable.
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from baseline to week one of therapy, all four TOPs on average
resulted in smaller reductions in viral load and this effect was
nominally significant for the three sites in NS2 and NS3 proteins.
As viral load is a surrogate for viral replication and virion pro-
duction, its reduction during therapy is an independent measure
that can highlight impact on treatment.
We studied the impact of these novel TOPs in an independent
cohort of patients treated with sofosbuvir in combination with
other DAAs regimes such as NS5A inhibitors (daclatasvir or
ledipasvir). The direction and estimated effect sizes were con-
sistent for three of the four sites. However, the associations were
not significant as the confidence intervals were larger. It is
important to note that this is not an equivalent replication cohort
due to its small size (144 patients) and the fact that majority of
patients were treated with other DAA in combination with
sofosbuvir, which will reduce the power for detecting associations.
Additionally, therapy including sofosbuvir as the only DAA is no
longer recommended and a cohort similar to BOSON is unlikely
to be available in the future.
In conclusion, our data show that common HCV gt3a poly-
morphisms in NS2 and NS3 proteins are associated with sofos-
buvir treatment outcome. Assessing these polymorphisms may be
useful in directing therapy length and combinations for difficult
to treat patients such as those with advanced cirrhosis or those
who have failed DAA therapy previously. Patients carrying both
NS2 132V and NS3 67V TOPs had the lowest SVR rate (50%) and
the smallest reduction in viral load during the first week of
therapy. Patients with these polymorphisms may require special
attention if treated using sofosbuvir containing therapies. Sofos-
buvir is only used in combination with NS5A inhibitors for which
RAS are common in baseline HCV sequences. In such cases
polymorphisms that reduces the impact of sofosbuvir will be
important in deciding the length and the combination of drugs
especially in difficult to treat groups.
Methods
Patients and samples
BOSON clinical trial. Our study is based on the analysis of samples from the
BOSON clinical trial20 (registration number: NCT01962441) and permission was
granted for the use of samples for further studies. Plasma Samples were obtained at
baseline, during treatment and 12 weeks post treatment. The patients were ran-
domised into three treatment arms of 12 Weeks SOF+ RBV+ IFN, 16 weeks
SOF+ RBV and 24 weeks SOF+ RBV. All patients were DAA treatment-naïve.
Each patient’s HCV viral load was measured at baseline, week 1, week 2, week 4
and week 8. All patients provided written informed consent before undertaking any
study-related procedures. The BOSON study protocol was approved by each
recruiting institution’s review board or ethics committee before study initiation.
The study was conducted in accordance with the International Conference on
Harmonisation Good Clinical Practice Guidelines45 and the Declaration of Hel-
sinki. Sample sizes were determined by the available data.
Replication cohort. The results of the V-GWAS were replicated using whole HCV
genome sequences from 144 patients from an independent cohort (HCV Research
UK cohort46). All patients provided written informed consent before undertaking
any study-related procedures, The use of data for this study was approved by the
HCV Research UK Tissue and Data Access Committee. All patients were treated
with SOF containing regimens. As direction of effects were estimated in the pri-
mary cohort, one-sided tests were used to replicate the results in this cohort.
Treatment outcome was the response variable and presence/absence of the TOP
the explanatory variable. All the patients were cirrhotic and host genotyping data
was not available. Therefore, we did not include any covariates in this analysis.
Viral sequencing. RNA was extracted from 500 μl of plasma using the NucliSENS®
easyMAG system (bioMérieux) into 30 μl of water, of which 5 μl was processed
with the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (New
England Biolabs) with previously published modifications to the manufacturers
protocol47. A 500 ng aliquot of the pooled library was enriched using the xGen®
Lockdown® protocol from IDT (Rapid Protocol for DNA Probe Hybridisation and
Target Capture Using an Illumina TruSeq® Library (v1.0), Integrated DNA
Technologies) with a comprehensive panel of HCV-specific 120 nucleotide DNA
oligonucleotide probes (IDT), designed using a previously published algorithm48.
The enriched library was sequenced using Illumina MiSeq v2 chemistry to produce
paired 150b reads. Reads were demultiplexed low-quality reads were trimmed with
QUASR(v7.0120) and adapter sequences removed using Cutadapt(v1.7.1). Host
derived sequences were removed using Bowtie(v2.2.4). HCV reads were selected by
mapping against the 162 ICTV (International Committee on the Taxonomy of
Viruses) reference sequences for mapping against the closest reference and de novo
assembly (Vicuna(v1.3)), read mapping (MOSAIK(v2.2.28)), genome annotation
(VFAT(v1.0)) and interpretation of variants (genewise2, Vphaser(v.2.0), Vprofi-
ler(v1.0)). HCV subtype was assigned based on the sequence similarity to ICTV
reference sequences, a phylogenetic tree of BOSON sequences and some ICTV
reference sequences can be found Supplementary Fig. 6.
Statistical methods. All statistical analysis was performed using the statistical
package R(v3.6.1), all the analysis code and data is available on request from the
STOP-HCV consortium (www.stop-hcv.ox.ac.uk).
Non-viral factors associated with outcome. To ensure we accounted for possible
confounders when investigating viral effects on outcome, a multivariate analysis
was performed using logistic regression to identify non-viral factors, which are
associated with SVR. The patient’s cirrhosis status, IFNL4 genotype, prior treat-
ment status, gender, log of baseline viral load and age at time of treatment were
investigated as possible confounders. Akaike Information Criterion was used to
choose the set of covariates to include in the model. The resulting model (Sup-
plementary Fig. 1) included, patient’s cirrhosis status, IFNL4 genotype, prior
treatment status, gender and log of baseline viral load as covariates in subsequent
regression-based analysis unless otherwise stated.
Previously reported sofosbuvir RAS effect on outcome. The effect of previously
reported sofosbuvir RAS present before treatment was investigated using logistic
regression. The response variable was treatment outcome (SVR), the explanatory
variable was the presence of RAS and the previously discussed non-viral factors
associated with outcome were included as covariates along with the first three viral
sequence and host genotyping principle components.
Phylogenetics and association of a phenotype with tree structure. RAxML(v8.0)49
was used to build a maximum likelihood phylogenetic tree using the HCV full
genome sequences assuming the general time reversible model of nucleotide sub-
stitution under the gamma model of rate heterogeneity. The treeBreaker(v1.0)23
software was then used to investigate if SVR or any novel TOP are associated with
specific clades on the tree. If any clades were associated with any of the novel TOP,
then the logistic regression was repeated adding an indicator variable for the
samples under the clade as a covariate, to confirm that the virus population
structure was not confounding the association.
Viral genome-wide association study. To investigate the effect of individual viral
amino acid polymorphisms on SVR a GWAS was performed using a logistic
regression model. In our analysis, SVR status was used as the response variable and
the presence and absence of each amino acid as the explanatory variable, the non-
viral factors previously indicated were included as covariates. To ensure that host-
virus population co-structuring had minimal impact on our analysis, we limited
our cohort to patients infected with HCV gt3a. To control for both host and virus
population structures we included the first three viral PCs calculated from viral
sequences and the first three host PCs calculated from the host genome-wide
genotyping data as covariates in our model.
Covariation and interaction of TOPs analysis. Logistic regression was used to test
for association between the number of TOPs in a patient’s viral sequence and SVR.
The response variable was SVR and the explanatory variable was number of TOPs
in the sequence, the non-viral factors previously indicated were included as cov-
ariates. We used logistic regression to investigate possible covariation of TOPs and
the first 3 viral PCs and IFNL4 genotype (CC/non-CC) were added as cofounders
as IFNL4 has been identified as having an effect on the viral genome. Interaction
was tested using logistic regression using interaction terms and the confounders
identified in Supplementary Fig. 1.
Initial response to therapy. To test if any TOP were associated with a smaller
reduction in VL at the start of therapy. The Log10 reduction in viral load from BL
to week1 of therapy was calculated. Wilcoxon tests were used to test if patients with
TOPs had a lower reduction in viral load than those who did not. Linear regression
with the confounders identified in Supplementary Fig. 1 included was used to test
for an association between the number of TOPs in a sequences and
reduction in VL.
Enrichment of an amino acid in the post-treatment HCV sequences. To test for
enrichment of an amino acid in the post-treatment samples (that did not achieve
SVR), we used a one-sided binomial test. For each amino acid, the frequency of the
amino acid in the baseline sequences, the total number of post-treatment sequences
and the observed number of the amino acid in the post-treatment sequences was
used to test for its enrichment in the post-treatment sequences.
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In vitro testing
Cell culture and generation of DBN3acc mutant viruses. All cell culture experiments
were performed in human hepatoma cells (Huh7.5 clone) as described using the
genotype 3a cell culture adapted DBN3acc system24. Mutations were introduced in
the DBN3acc plasmid using a megaprimer approach with primers described in
Supplementary Table 4 at a final concentration of 10 µM, 50 ng of plasmid tem-
plate, and the Q5 High-Fidelity 2X Master Mix reagent. For the first PCR cycling
conditions were 98 °C for 30 s, followed by 35 cycles of: 98 °C for 10 s, 71 °C for
15 s, and 72 °C for 1 min, followed by a final extension at 72 °C for 5 min. The PCR
products were treated overnight with DpnI (NEB) at 37 °C and gel purified using
the Zymoclean Gel DNA Recovery Kit (Zymo Research). 200 ng of the amplicon
were used as primer in a second PCR reaction (megaprimer reaction) with 50 ng of
plasmid template conducted at 98 °C for 30 s, followed by 20 cycles of: 98 °C for
10 s, 48 °C for 1 min, and 72 °C for 20 min, followed by a final extension at 72 °C
for 20 min. The PCR products were treated overnight with DpnI (NEB) and 2 µl of
product was transformed in XL10-Gold ultracompetent cells (NEB) following the
manufacturer’s protocol. All plasmid preparations (Qiagen) were confirmed by
Sanger sequencing.
Plasmids were linearised with XbaI (NEB) and treated with Mung Bean nuclease
(NEB) prior to in vitro transcription (IVT). IVT were performed using 2 µg of template
using the MEGAscript T7 Transcription Kit (Thermo Fisher Scientific) and following
the manufacturer’s instructions. RNA IVT transcripts were purified using the RNeasy
mini Kit (Qiagen). Transfections were performed with lipofectamine 2000 (Thermo
Fisher Scientific) and cells were seeded 24 h prior to the experiment in 6-well plates
(5 × 105 cells per well). In brief 5 µl of diluted lipofectamine in 245 µL of Optimem
(Thermo Fisher Scientific) was mixed with 2.5 µg of viral RNA also diluted in Optimem
(final volume of 250 µl). The RNA/lipofectamine mix was incubated at room
temperature for 20min and added to cells containing Optimem. After 4 h of incubation
at 37 °C, the media was replaced by regular culture media (DMEM (high glucose,
GlutaMAX and pyruvate, Invitrogen ThermoFisher) supplemented with 10% fetal
bovine serum (Sigma), 100 units/ml of penicillin and 0.1mg/ml of streptomycin/ml
[Sigma]). Cultures were split every 2–3 days and virus containing supernatant was
harvested, filtered and stored at −80 °C. The viral infection was monitored by
immunostaining of HCV viral antigens with mouse monoclonal [C7-50] anti-core
(#ab2740, Abcam) and mouse monoclonal 9E10 anti-NS5A antibodies24,50 followed
by addition of Goat anti-Mouse IgG (H+ L) Highly Cross-Adsorbed Secondary
Antibody, Alexa Fluor Plus 488 (#A32723, Invitrogen) and Hoechst counter-stain
(#33342, Life Technologies)24. The number of HCV antigen protein-positive cells were
evaluated by fluorescence microscopy (Axio Vert.A1; Zeiss, Jena, Germany). One
millilitre of supernatant harvested at days 14 or 17 post-transfection was used for
passage of naïve Huh7.5 cells. Supernatants harvested at day 8 post-infection were used
for the analysis of the HCV viral sequence (complete ORF)51. Extraction and
purification of viral RNA was performed using Trizol™ LS (Life technologies),
chloroform (Sigma) and the RNA clean & concentrator™−25 kit (Zymo research)
following manufacturer’s instructions. Synthesis of cDNA was performed with the
Maxima H minus reverse transcriptase system (Thermo Scientific), supplemented
with RNasin plus RNase inhibitor enzyme (Promega) and with reverse primer
5′-AAAAGAATGGAGTGTTATC-3′. cDNA was treated with RNase H (Takara) and
RNase T1 (Thermo Scientific) and immediately used as template for the PCR
amplification. A single amplicon encompassing the entire viral ORF (from nt.293 to
nt.9432, [DBN3acc numbering and primers 5′-GATAGGGTGCTTGCGAGTGCC-3′
and 5′-AGAATGGAGTGTTATCCTACCAGCTCA-3′]) was obtained using the Q5®
Hot Start High-Fidelity DNA polymerase system (NEB) with PCR cycling conditions as
follows: 1 cycle of 98 °C/30 s; 35 cycles of 98 °C/10 s, 65 °C/10 s and 72 °C/8min; and 1
cycle of 72 °C/1min. Purified PCR products (DNA Clean & Concentrator™-25 [Zymo
research]) were sent for Sanger sequencing (Macrogen Europe). Obtained
chromatograms were visually inspected and assembled using Sequencher 5.3 software
(Gene Codes Corporation). Nucleotide polymorphisms were compared with
corresponding reference sequences and reported.
Viral titration of harvested transfection supernatants was performed with a
focus-forming units (FFU) assay24,34. Cells were seeded in 96-well plates with flat
bottom and the next day, 100 μl of 10-fold serially diluted viral supernatants were
added in triplicates. Cells were fixed with methanol (Sigma) after 48 h. HCV-
specific immunostaining was performed with [C7-50] anti-core and mouse
monoclonal 9E10 anti-NS5A antibodies, followed by addition of secondary
antibody (ECL sheep anti-mouse IgG horsedish-peroxidase linked whole antibody
[#NA931, GE Healthcare]) and staining with 3,3′-diaminobenzidine (DAB)
substrate kit (#KBS04-500, Immunologic). The number of focus-forming units was
determined with an automated cell counting system (Cellular Technology limited,
CTL) and transformed to Log10FFU/ml.
Evaluation of resistance phenotype. Treatment assays with sofosbuvir consisted of
dose-response assays and determination of effective 50% concentrations (EC50)
conductedr as previously described24,34. Cells were plated in 96-well plates with flat
bottom and the next day infected in triplicates for 24 h and thereafter treated with
sofosbuvir for 48 h. Cells were then fixed and stained as described above and the
counts of HCV antigen-positive cells at the different drug concentrations were
related to the counts of non-treated controls. Dose-response curves were generated
with the GraphPad Prism software (version 9) using the formula Y= Top/
(1+ 10[Log10 EC50 - X] *Hill slope). One experiment with four replicates was
performed for each virus. Changes in drug susceptibility for the mutant viruses
were calculated as fold-EC50 change (EC50 mutant/EC50 original virus).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The HCV sequence data have been deposited in GenBank database under accession
codes KY620313–KY620880. The raw clinical data is available on request at http://
www.stop-hcv.ox.ac.uk/data-access. Source data are provided with this paper.
Code availability
The R code used to generate the results and figures from the primary analyses described
above are available from the authors on request.
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